- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07444268
Comment le [14C]-DSP-5336 est absorbé, dégradé et éliminé de l'organisme après une dose orale unique chez des patients atteints de cancers du sang avancés
Étude de phase 1, ouverte, de l'absorption, du métabolisme et de l'excrétion du DSP-5336 après administration orale unique chez des patients atteints de leucémie aiguë réfractaire ou en rechute, de syndrome myélodysplasique, de myélome multiple ou de néoplasmes myéloprolifératifs
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- University of North Carolina
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- MD Anderson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female, of any race, ≥ 18 years of age. Female patients must be surgically sterile or postmenopausal. Male patients must be permanently sterile or agree to use contraception.
- Have an advanced hematological malignancy that is relapsed, refractory, or has progressed following receipt of standard and available treatments.
- Any prior pre-treatment toxicities resolved to ≤Grade 1 prior to enrolment, with exception of ≤Grade 2 alopecia or neuropathy.
- Adequate kidney and liver function
- ECOG performance status of ≤ 2.
- Able to attend the required study visits, including the confinement period for monitoring and collection of bowel movements and micturition.
- Able to comprehend and are willing to sign the ICF and abide by the study restrictions.
Exclusion Criteria:
- Histologic diagnosis of acute promyelocytic leukemia.
- Abnormal ECG that is clinically significant, such as QTcF > 480 msec. QT interval correction can be performed in the case of bundle branch block.
- History of torsades de pointes.
- Left ventricular ejection fraction ≤ 45%, as determined by echocardiogram.
- Have any concurrent conditions that could pose an undue risk or interfere with interpretation of the study results, including, but not limited to clinically significant non-healing or healing wounds, concurrent congestive heart failure, unstable angina, cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation), myocardial infarction within 6 months, acute coronary syndrome within 6 months, significant pulmonary disease (shortness of breath at rest or on mild exertion; eg, due to concurrent severe obstructive pulmonary disease, hypertension not controlled with concomitant medication, or diabetes mellitus with > 2 episodes of ketoacidosis in the prior 6 months).
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).
- History or evidence of severe dysphagia, short-gut syndrome, gastroparesis, gastrointestinal tract disease, malabsorption syndrome, the requirement for intravenous alimentation, gastric/jejunal feeds, any uncontrolled gastrointestinal disease, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally, including the inability to swallow oral medication
- Have cognitive, psychological, or psychosocial impediment that would impair their ability to receive therapy according to the protocol or would adversely affect their ability to comply with the informed consent process, protocol, or protocol-required visits and procedures.
- History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of check-in, unless approved by the investigator and medical monitor.
- Active and uncontrolled bacterial, viral, or fungal infection requiring parenteral therapy.
- Positive hepatitis panel and/or positive human immunodeficiency virus test indicative of active infection. Patients whose results are compatible with prior immunization may be included.
- Undergone HSCT, chimeric antigen receptor cell therapy, or other modified T-cell therapy within 60 days prior to dosing.
- Received donor lymphocyte infusion within 28 days prior to dosing, receiving immunosuppressive therapy post-HSCT, or have clinically active GVHD or GVHD requiring active medical intervention other than the use of topical steroids for ongoing cutaneous GVHD.
- Received systemic calcineurin inhibitors within 2 weeks prior to dosing.
- Received other anticancer drugs or other investigational treatment within 14 days or 5 half-lives, whichever is shorter, prior to dosing.
- Major surgery within 28 days prior to dosing.
- Any known intolerance or hypersensitivity to components of the study intervention.
- Patients who have previously been dosed in > 2 radiolabeled drug studies in the last 12 months. For patients who have previously been dosed in ≤ 2 radiolabeled drug studies within the last 12 months, the previous radiolabeled dose must be at least 4 months prior to check-in to the study site where exposures are known to the investigator or 6 months prior to check-in to the study site for a radiolabeled drug study where exposures are not known to the investigator.
- Poor peripheral venous access.
- Patients with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
- Patients who, in the opinion of the investigator or designee, should not participate in this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: DSP-5336 tablets and [14C]-DSP-5336 solution
Part 1 |
tablet oral solution |
|
Expérimental: Optional Continued Access
Part 2 |
tablet |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total recovery of radioactivity in urine as percentage of total radioactive dose of [14C]-DSP-5336
Délai: Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
The percentage of dose excreted in urine |
Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
|
Total recovery of radioactivity in fecal waste as percentage of total radioactive dose of [14C]-DSP-5336
Délai: Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
The percentage of dose excreted in fecal waste |
Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
|
Total recovery of radioactivity in excreta balance as percentage of total radioactive dose of [14C]-DSP-5336
Délai: Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
The percentage of dose excreted in combined urine and fecal waste |
Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
|
Relative abundance (mean value) of [14C]-DSP-5336
Délai: 4 days, max 7 days
|
Plasma samples will be analyzed for [14C]-DSP-5336 and its metabolites. |
4 days, max 7 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Area under the plasma concentration time profile from time zero to time of the last quantifiable concentration (AUClast) of [14C]-DSP-5336
Délai: 4 days, max 7 days
|
The determination of AUClast using the linear/log trapezoidal rule |
4 days, max 7 days
|
|
Cmax for the relative bioavailability of [14C]-DSP-5336
Délai: 4 days, max 7 days
|
Analysis of the maximum concentration (Cmax) of the relative bioavailability of [14C]-DSP-5336 utilizing the ratio of the adjusted geometric means |
4 days, max 7 days
|
|
t(1/2) of [14C]-DSP-5336
Délai: 4 days, max 7 days
|
Elimination half-life (t[1/2]) of [14C]-DSP-5336 |
4 days, max 7 days
|
|
Ratio of plasma to whole blood total radioactivity
Délai: 4 days, max 7 days
|
The fraction of [14C]-DSP-5336 radioactivity associated with whole blood and plasma and with red blood cells and other cellular components of whole blood was determined by using the concentration of [14C]-DSP-5336 radioactivity in whole blood and plasma |
4 days, max 7 days
|
|
Number of participants with adverse events and serious adverse events
Délai: 30 days
|
Safety of DSP-5336 by reporting of AEs and SAEs |
30 days
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- DSP-5336-102
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .